General Information
Drug ID
DR01204
Drug Name
Norfloxacin
Synonyms
1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid; AM 0715; AM 715; AM-0715; AM-715; AM0715; Apo-Norflox (TN); Baccidal; Barazan; Chibroxin; Chibroxin (TN); Chibroxin, MK-366, Baccidal, Sebercim, Zoroxin, Norfloxacin; Fulgram; Insensye (TN); Lexinor; MK 0366; MK 366; MK-0366; MK-366; MK0366; MK366; Merck Brand of Norfloxacin; NFLX; Norflo; Norflohexal (TN); Norfloxacin (JP15/USP/INN); Norfloxacin Merck Brand; Norfloxacin [USAN:BAN:INN:JAN]; Norfloxacine; Norfloxacine [INN-French]; Norfloxacino; Norfloxacino [INN-Spanish]; Norfloxacinum; Norfloxacinum [INN-Latin]; Norfocin (TN); Noroxin; Noroxin (TN); Nufloxib (TN); Roxin (TN); Sebercim; Utin (TN); Utinor (TN)
Drug Type
Small molecular drug
Indication Urinary tract infections [ICD11: GC08] Approved [1]
Gynecological infections [ICD11: GA6Z] Approved [1]
Therapeutic Class
Antibiotics
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=4539"></iframe>
3D MOL 2D MOL
Formula
C16H18FN3O3
Canonical SMILES
CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O
InChI
InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)
InChIKey
OGJPXUAPXNRGGI-UHFFFAOYSA-N
CAS Number
CAS 70458-96-7
Pharmaceutical Properties Molecular Weight 319.336 Topological Polar Surface Area 72.9
Heavy Atom Count 23 Rotatable Bond Count 3
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 7
XLogP
-1
PubChem CID
4539
PubChem SID
10321598 , 11112831 , 11335259 , 11360498 , 11363911 , 11366473 , 11369035 , 11371707 , 11374005 , 11377197 , 11461470 , 11466249 , 11467369 , 11484909 , 11485918 , 11488833 , 11490340 , 11492268 , 11494831 , 12013332 , 14715876 , 14874649 , 26611845 , 26680206 , 26746929 , 26746930 , 29223630 , 3205552 , 46508634 , 4712110 , 47440088 , 47440089 , 47440090 , 47515159 , 47736303 , 47736304 , 47810598 , 47959570 , 47959571 , 48034947 , 49698389 , 50042536 , 50100528 , 597742 , 7847277 , 7980171 , 8149451 , 8152796 , 855614 , 8912
ChEBI ID
CHEBI:100246
TTD Drug ID
D0Q2PE
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
OATP1A2 Transporter Info Organic anion transporting polypeptide 1A2 Substrate [3]
P-GP Transporter Info P-glycoprotein 1 Substrate [4]
References
1 Norfloxacin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos. 2006 Apr;34(4):690-5.
3 Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
4 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.